A1ESZ

(2~{Z},5~{Z})-5-[[4-[(2~{R})-2,3-bis(oxidanyl)propoxy]-3-chloranyl-phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one

Created:2025-07-06
Last modified:  2026-01-28

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count56
Chiral Atom Count1
Bond Count58
Aromatic Bond Count12
2D diagram of A1ESZ
Toggle HydrogenToggle Labels

Chemical Component Summary

Name(2~{Z},5~{Z})-5-[[4-[(2~{R})-2,3-bis(oxidanyl)propoxy]-3-chloranyl-phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
SynonymsPonesimod
Systematic Name (OpenEye OEToolkits)(2~{Z},5~{Z})-5-[[4-[(2~{R})-2,3-bis(oxidanyl)propoxy]-3-chloranyl-phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
FormulaC23 H25 Cl N2 O4 S
Molecular Weight460.974
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385CCCN=C1SC(=Cc2ccc(OC[CH](O)CO)c(Cl)c2)C(=O)N1c3ccccc3C
SMILESOpenEye OEToolkits2.0.7CCCN=C1N(C(=O)C(=Cc2ccc(c(c2)Cl)OCC(CO)O)S1)c3ccccc3C
Canonical SMILESCACTVS3.385 CCCN=C1S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c3ccccc3C
Canonical SMILESOpenEye OEToolkits2.0.7 CCC/N=C\1/N(C(=O)/C(=C/c2ccc(c(c2)Cl)OC[C@@H](CO)O)/S1)c3ccccc3C
InChIInChI1.06 InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23-/t17-/m1/s1
InChIKeyInChI1.06 LPAUOXUZGSBGDU-STDDISTJSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB12016 
NamePonesimod
Groups
  • investigational
  • approved
DescriptionPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].[A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.[A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709]
SynonymsPonesimod
Brand NamesPonvory
IndicationPonesimod is indicated to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[L32709]
Categories
  • Antineoplastic and Immunomodulating Agents
  • Cytochrome P-450 CYP3A Substrates
  • Cytochrome P-450 CYP3A4 Substrates
  • Cytochrome P-450 CYP3A5 Substrates
  • Cytochrome P-450 Substrates
ATC-CodeL04AE04
CAS number854107-55-4

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Sphingosine 1-phosphate receptor 1MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISADKENSIKLTSV...unknownagonist,modulator,regulator
Cytochrome P450 2J2MLAAMGSLAAALWAVVHPRTLLLGTVAFLLAADFLKRRRPKNYPPGPWRL...unknownsubstrate
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate
Cytochrome P450 4F3MPQLSLSSLGLWPMAASPWLLLLLVGASWLLARILAWTYTFYDNCCRLRC...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682